Table 3.

Statistical analyses of achievement of MR4.0

Univariate analysisFirst-line therapy and sex adjusted
n (%)HR (95% CI)PHR (95% CI)P
KIR2DL1 (2 vs. 1)65 (85.5)0.859 (0.405–1.821)0.6921.268 (0.585–2.748)0.548
KIR2DL2 (1 vs. 0)12 (15.8)1.243 (0.606–2.546)0.5531.115 (0.534–2.330)0.772
KIR2DL3 (2 vs. 1)64 (84.2)0.805 (0.393–1.648)0.5531.115 (0.534–2.330)0.772
KIR2DL5 (1, 2 vs. 0)29 (37.8)1.026 (0.983–1.071)0.2361.02 (0.976–1.066)0.38
KIR2DS1 (1, 2 vs. 0)27 (35.5)1.023 (0.980–1.068)0.2951.015 (0.971–1.061)0.517
KIR2DS2 (1 vs. 0)12 (15.8)1.243 (0.607–2.546)0.5530.897 (0.429–1.874)0.772
KIR2DS3 (1, 2 vs. 0)8 (10.5)1.003 (0.939–1.071)0.931.024 (0.958–1.095)0.478
KIR2DS4 (2 vs. 0, 1)49 (64.5)0.966 (0.906–1.031)0.2950.978 (0.916–1.045)0.517
KIR2DS5 (1 vs. 0)20 (26.3)1.430 (0.823–2.483)0.2051.151 (0.652–2.034)0.627
KIR3DL1 (2 vs. 0, 1)49 (64.5)0.966 (0.906–1.031)0.2950.978 (0.916–1.045)0.517
KIR2DL1 positive/HLA-C2 positive10 (13.2)2.521 (1.209–5.258)0.0141.915 (0.890–4.122)0.097
KIR2DL2 positive/HLA-C1 positive12 (15.8)1.243 (0.607–2.546)0.5531.115 (0.534–2.330)0.772
KIR3DL1 positive/HLA-Bw positive64 (84.2)0.539 (0.276–1.055)0.0710.725 (0.368–1.430)0.353
KIR2DL4*005/011 or *00840 (52.6)1.942 (1.160–3.250)0.0121.797 (1.052–3.067)0.032
KIR2DS4*003 or *007/01020 (26.3)3.878 (2.125–7.075)<0.0013.348 (1.773–6.323)<0.001
KIR3DL1*00514 (18.4)3.634 (1.884–7.013)<0.0012.746 (1.403–5.376)0.003
KIR3DL2*009 or *01022 (28.9)1.864 (1.067–3.258)0.0291.980 (1.109–3.524)0.021
Activating KIR positive35 (46.1)1.383 (0.830–2.304)0.2141.094 (0.636–1.881)0.745
KIR haplotype A/A41 (53.9)0.723 (0.434–1.205)0.2140.914 (0.532–1.572)0.745
Female sex29 (37.8)1.709 (1.028–2.842)0.039N/A
Age 65 years and over22 (28.9)1.262 (0.718–2.219)0.4191.180 (0.651–2.138)0.586
Sokal score low vs. highLow: 39 (51.3%)0.635 (0.306–1.316)0.2220.462 (0.218–0.982)0.045
Sokal score intermediate vs. highInt: 24 (31.6%)0.594 (0.271–1.302)0.1930.384 (0.168–0.881)0.024
Sokal score low vs. intermediateHigh: 10 (13.2%)1.001 (0.566–1.770)0.9971.033 (0.582–1.833)0.913
First-line dasatinib or nilotinib46 (60.5)7.305 (3.377–15.803)<0.001N/A